|
|
Volumn 34, Issue 5, 2002, Pages 1730-1732
|
|
Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYTOCHROME P450 3A4;
INTERLEUKIN 2 RECEPTOR ANTIBODY;
METHYLPREDNISOLONE;
PREDNISONE;
TACROLIMUS;
BASILIXIMAB;
HYBRID PROTEIN;
IMMUNOSUPPRESSIVE AGENT;
MONOCLONAL ANTIBODY;
ADULT;
ANALYSIS OF VARIANCE;
CLINICAL ARTICLE;
CONFERENCE PAPER;
CONTROLLED STUDY;
DRUG BLOOD LEVEL;
DRUG DETERMINATION;
DRUG EFFECT;
DRUG MONITORING;
ENZYME METABOLISM;
FEMALE;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
KIDNEY GRAFT REJECTION;
KIDNEY TRANSPLANTATION;
LIVER FUNCTION TEST;
MALE;
MEDICAL RECORD;
PRIORITY JOURNAL;
QUANTITATIVE ANALYSIS;
RECIPIENT;
STATISTICAL SIGNIFICANCE;
STUDENT T TEST;
ARTICLE;
BLOOD;
COMPARATIVE STUDY;
DRUG INTERACTION;
IMMUNOLOGY;
METABOLIC CLEARANCE RATE;
MIDDLE AGED;
PHYSIOLOGY;
RETROSPECTIVE STUDY;
ANTIBODIES, MONOCLONAL;
DRUG INTERACTIONS;
FEMALE;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
KIDNEY TRANSPLANTATION;
MALE;
MEDICAL RECORDS;
METABOLIC CLEARANCE RATE;
METHYLPREDNISOLONE;
MIDDLE AGED;
RECOMBINANT FUSION PROTEINS;
RETROSPECTIVE STUDIES;
TACROLIMUS;
|
|
EID: 0035993387
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/S0041-1345(02)03000-2 Document Type: Conference Paper |
|
Times cited : (39)
|
|
References (9)
|
